WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceutical company that develops targeted anticancer therapeutics, today announced the promotion to vice president of two executive directors – Godfrey Amphlett, Ph.D., and Robert J. Lutz, Ph.D. – who have played central roles in establishing ImmunoGen’s highly successful product development capabilities. These functions complement the Company’s strong research capabilities in ImmunoGen’s advancement of its own novel anticancer compounds and the industry-leading target-to-commercial product expertise the Company provides to its partners.
